Streetbeat News

VNRX

VolitionRx Limited

https://www.volition.com

Industry

Medical - Diagnostics & Research

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. It sells Nu.Q that detect cancer; Nu.Q Nets, monitoring the immune system; Nu.Q Vet cancer screening test for veterinary applications; Nu.Q Capture capturing and concentrating samples for more accurate diagnosis; and Nu.Q Discover, a solution to profiling nucleosomes. The company operates Nucleosomics a technology platform for blood test. VolitionRx Limited is based in Austin, Texas.

Open

0.57

Mkt cap

52M

Volume

81K

High

0.58

P/E Ratio

-1.51

52-wk high

1.02

Low

0.53

Div yield

N/A

52-wk low

0.43

VolitionRx Limited has announced a novel Nu.Q® Cancer immunoassay test that can detect 21 different cancers with high accuracy and low false positive rates. The test can potentially be used as a standalone pan-cancer screening method or licensed to other diagnostic companies. The study showed 86% overall detection accuracy, particularly for fatal cancers like lung, breast, prostate, colon, and liver.

Portfolio Pulse from

March 21, 2025 | 12:45 pm

Portfolio Pulse from

March 21, 2025 | 12:45 pm

VolitionRx Limited has introduced a new industry primer for its Nu.Q® Cancer Blood Test, aimed at transforming lung cancer diagnosis, treatment, and monitoring in the $4 billion market.

Portfolio Pulse from

March 20, 2025 | 12:45 pm

VolitionRx Limited has introduced a new industry primer titled 'Lung Cancer: Hope of a Brighter Tomorrow', highlighting their Nu.Q® Cancer Blood Test. This test aims to revolutionize the diagnosis, treatment, and monitoring of lung cancer, a market valued at $4 billion.

Portfolio Pulse from

March 20, 2025 | 12:45 pm

VolitionRx Limited (NYSE AMERICAN: VNRX) is sponsoring and hosting presentations at the 44th ISICEM Congress in Brussels, Belgium, from March 18-21, 2025. This participation highlights Volition's involvement in the field of intensive care and emergency medicine.

Portfolio Pulse from

March 18, 2025 | 11:30 am

Portfolio Pulse from

March 17, 2025 | 12:45 pm

VolitionRx Limited has expanded its agreement with Fujifilm Vet Systems to include the automated version of its Nu.Q® Vet Cancer Test, using the IDS i10® platform, for a five-year term.

Portfolio Pulse from

March 13, 2025 | 12:45 pm

Volition has announced the enrollment of the first patient in NTU Hospital's study to validate the Nu.Q® Lung Cancer Test, which differentiates between malignant and benign nodules. The study is expected to conclude by the end of 2025.

Portfolio Pulse from

March 11, 2025 | 12:45 pm

VolitionRx Limited has signed an agreement with a leading pharmaceutical company to use its Nu.Q® Discover biomarkers in a Phase 1/2b clinical study. This marks the first time these biomarkers will be used in a human clinical study.

Portfolio Pulse from

March 04, 2025 | 1:45 pm

VolitionRx Limited (NYSE AMERICAN: VNRX) is showcasing its Nu.Q® Vet Cancer Test at the 97th Annual Western Veterinary Conference, a major event for veterinary professionals.

Portfolio Pulse from

February 28, 2025 | 1:45 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.